3 Shares On My Watchlist Should The Market Meltdown: Rolls-Royce Holding plc, Aviva plc & GlaxoSmithKline plc

Rolls-Royce Holding plc (LON:RR), Aviva plc (LON:AV) & GlaxoSmithKline plc (LON:GSK) are on this Fool’s watchlist should the market tumble…

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After two days of uncertainty, the market breathed a nervous sigh of relief on Wednesday, this despite Greece being the first developed country to actually default on its debt. Even now, there is speculation aplenty as to whether the politicians can actually agree a workable solution to this debacle, which keeps both the lenders and the Greek People happy.

As we all should know by now, the market hates uncertainty, and I suspect that there will be plenty more volatility to come over the coming days, weeks and possibly months as we watch this crisis play out.

Whichever way the people decide to go, should they still go to the polls this Sunday, there will be plenty of pain in the years ahead.

As an investor, whilst mindful of the human cost that this crisis brings, it is my job to look for opportunities that this crisis presents to me. With that in mind, let me share three companies currently in my sights:

Rolls Royce Holdings…

Readers here may be a little surprised to see a company that has issued a string of profit warnings since October last year, but I do tend to get a little interested when blue-chip organisations like Rolls Royce (LSE: RR) — or more to the point, their share price — crash by nearly 50% over the last 18 months.

That said, as I have stated before, the share price can continue to sink as the market wakes up to the fact that it could be some time before the business starts to fire on all cylinders again – if at all. Add a little uncertainty about Europe and the possible ramifications on the global economy, and you can see why I might want a higher margin of safety than I may normally ask.

With the shares trading at just over 14 times forward earnings and yielding under 3%, I’m happy to sit a wait a while longer.

But let’s be clear here – this is a company with an order book in excess of £70 billion, so it’s not really struggling for work. To my mind, it just needs to do that work more efficiently. The new man at the top is Warren East, formerly the CEO of ARM Holdings, and one of the executives that placed the company firmly on the map. This could be the man to turn the company’s fortunes around… should the market panic over Greece a little more, I may well get the entry point that I want to open a long-term position.

Aviva…

Some might argue that Aviva (LSE: AV) has been trying to turn around since 2012 when then-CEO Andrew Moss was forced out following the much publicised ‘shareholder spring’ attacked his pay packet – hardly surprising, as the share price was over 50% less than when he had taken charge, five years prior.

This led to the company embarking on a restructuring plan, including job cuts, selling off non-core operations and expanding into new growth markets, such as Asia.

This has continued under the new CEO, Mark Wilson, who — as the new broom — made the decision to cut the dividend and helped steer the company to better-than-expected profits in the year ending 2013.

The company has also now completed on the deal which has bought Friends Life Group into the fold. The deal boosts its customers by almost 50% and trims over £200 million of annual costs.

Additionally, the group raised its final dividend by 30% — rises like this give me confidence that the group is turning itself around. Whilst the CEO admits that there is still work to be done, the shares are starting to look very interesting, trading at around 10 times forward earnings and yielding nearly 5%.

GlaxoSmithKline…

GlaxoSmithKline (LSE: GSK) is currently in the process of working through the Novartis deal that it announced last year.

Mr Market is currently a little uncertain regarding the strategic review coupled with the fact that the dividend is being held at 80p per share over the next three years. Additionally, the proposed return to shareholders of £4 billion of proceeds from the Novartis transaction was reduced to £1 billion: this will be paid in the fourth quarter along with the final dividend. Whilst this creates more breathing room for the company, the market was disappointed by the news.

At current prices, investors know that they have a rather safe 6%+ yield for the next three years.

That’s not a bad return whilst we wait for the strategic review to work through the company. Whilst some might argue that the lack of growth makes Glaxo unattractive, I believe that dividend growth could well resume in 2017: should the company’s strategy play out as expected, it should be in a stronger financial position, allowing it to resume growing the dividend.

Going forward, the company intends to target emerging markets for much of the company’s growth, with an increased focus on vaccines and consumer healthcare. Helpfully, the vaccines business grew sales by 10% and revenue is forecast to grow at a CAGR (compound annual growth rate) of mid-to-high single digits out to 2020. This is an area the firm has invested in increased manufacturing capacity in anticipation of strong demand for its products.

The Price Is Right?

As you can see from the three-month chart below, all three shares have underperformed the FTSE 100. Should this continue with the market in panic over the possibility of a ‘Grexit’, patient long-term investors may well be able to bag themselves a bargain!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »